Royalty Pharma details royalties and funding from Novartis acquisition of MorphoSys at €68/share

Royalty Pharma plc

Royalty Pharma holds 3% royalty on pelabresib (myelofibrosis) and tulmimetostat (EZH2 inhibitor) future sales; NDA submission expected mid-2024.
Tiered mid-single digit royalty on Tremfya (J&J; $3.1B sales FY2023) and 3.3%-4.2% effective royalty on Roche's trontinemab for Alzheimer's.
MorphoSys to make 36 payments totaling ~$660M (2.2x funded $300M) to repay Development Funding Bonds, starting Q4 2024.
Royalty Pharma's 1,337,552 MorphoSys shares valued at ~$100M at proposed Novartis acquisition price.
Royalty Pharma had committed up to $2.025B funding to MorphoSys in July 2021 strategic partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.